Latest Breaking News On - Lung cancer non small cell - Page 1 : comparemela.com

Genmab A/S: Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive

United statesAsia pacificDavid freundelFosun pharmaAndrew carlsenAmerican society of clinical oncologyRoche groupExchange commissionGlobal communications corporate affairsAmerican cancer societyClinical oncologyAnnual meetingNon small cell lung cancerNorth americaMedia releaseAnnual report

Innate Pharma SA: Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting

Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate's second generation ANKET, for the treatment

United statesPierluigi porcuHenry wheelerCharu aggarwalOlivier demariaArthur rouillLorenzo falchiHirva mamdaniAmerican society of clinical oncologyExchange commissionFrench financial markets authorityHoosier cancer research networkCompany annual report on formB cell non hodgkinEuronext parisAmerican society

BioNTech SE: BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024

MAINZ, Germany, May 21, 2024 - BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline at the

United statesGenmab saFosun pharmaRoche groupBiotheus incAmerican society of clinical oncologyGenentech incAmerican societyClinical oncologyAnnual meetingChief medical officerLung cancer non small cellBispecific antibody targetingPoster boardSolid tumorsClinical data

Merus N V : Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Merus N V : Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomDennis riedlAmerican society of clinical oncologyExchange commissionClinical oncologyAnnual meetingLung cancer non small cellPrivate securities litigation reform actAnnual reportAktien sie

Ipsen : New investigational clinical data for Ipsen s oncology products in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting -Today at 11:53 am

Paris , 24 May 2019 - Ipsen today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib , liposomal irinotecan , and lanreotide autogel will.

United statesAlexandre lebeautCabozantinib nivolumabIpilimumab cabonivoipiIpsen euronextEuropean organization for researchRenal cell cancer allianceAmerican society of clinical oncologySomatuline depotClinical oncologyEuropean organizationExecutive vice presidentChief scientificNeck cancerIrinotecan liposome injectionSmall cell lung cancer